Calcium supplements and cardiovascular risk in the Women’s Health Initiative

Bolland, Mark J; Grey, Andrew; Reid, Ian R.

doi:10.1007/s00198-013-2356-z

Cited by 3 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these cohorts did not use any vitamin D-enriched dairy products [ 43 – 46 ], while our analysis is based on the intake of dairy products providing the amount of calcium and vitamin D, which are considered by most experts and recommendations from scientific organizations as appropriate to improve bone health [ 1 , 2 , 7 , 12 ]. Divergent opinion, challenging the interest of calcium and vitamin D in OP [ 47 ] or reporting putative increase in adverse effects following calcium supplementation [ 48 ] appear to be insufficiently substantiated [ 49 ] and, at any rate more directed towards calcium pharmacological supplementation than against dairy products intake [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures

et al. 2015

View full text Add to dashboard Cite

BackgroundDietary sources of calcium and vitamin D are recommended as a first-line strategy in prevention of osteoporosis-related fractures but their public health and economic impact has never been studied.MethodsWe designed a population-based model to forecast the potential health outcomes and medical effectiveness of the daily administration of dairy supplements containing 800 IU of vitamin D and 1 g of calcium in cohorts of subjects, from both genders, aged 50, 60, 70 and 80 years. Annual costs of dairy products were tested at €150, €250 and €350.ResultsIn total, the daily intake of vitamin-D rich dairy products reduces by 30,376 and 16,105 events the number of osteoporotic fractures in women and men respectively and permits to gain 6605 and 6144 life-years, in women and men respectively. This intervention is cost-effective from 70 years on in the general population and from 60 years on in patients at increased risk of osteoporotic fractures.ConclusionThe recommendation to use dairy products as the preferred source of calcium and vitamin D in aging males and females is supported by public health and health economic analyses.Electronic supplementary materialThe online version of this article (doi:10.1186/s13690-015-0099-3) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[30] Recently, concerns of associations between calcium supplements and cardiovascular events have been raised. [10,11] Our survey revealed that a half of participants changed their pattern of prescription for calcium.…”

Section: Discussionmentioning

confidence: 99%

“…[9] Although sufficient use of calcium should be necessary to gain the full effect of anti-osteoporosis drugs, some authors have warned the concerns on utilization of calcium for cardiovascular events. [10,11]…”

Section: Introductionmentioning

confidence: 99%

Physicians' Attitudes to Contemporary Issues on Osteoporosis Management in Korea

Lee

Lim

et al. 2014

J Bone Metab

View full text Add to dashboard Cite

BackgroundIn management of osteoporosis, several concerns here have been raised. The current issue included the utilization of dual energy X-ray absorptiometry (DXA) and fracture-risk assessment (FRAX), screening of vitamin D deficiency and secondary osteoporosis, and long-term use of bisphosphonate and calcium supplements. There was no study on physicians' attitude on these current issues in Korea. Therefore, we investigated the physicians' attitude on these issues by survey.MethodsWe administered a 30-item questionnaire to all members of Korean Society for Bone and Mineral Research by email survey form. One hundred participants answered the questionnaire. The questionnaire included the questions about the physicians' attitude to current issues and the barriers to osteoporosis treatment in Korea.ResultsMost physicians used bone densitometry devices (99%) and, central DXA was the most accessible device (95%). Eighty-eight percent were aware of FRAX®, but among them, only 19.3% used it. The main reason for not using FRAX® was the lack of time in their proactive (76%). Screening for vitamin D status and secondary osteoporosis was performed by 59% and 52% of the respondents, respectively. The lack of awareness among patients and high costs of medication were perceived as the most important barriers to osteoporosis management in Korea.ConclusionsThis study provides physicians' perspective to the current issue for diagnostic and treatment of osteoporosis in Korea. To further improve osteoporosis management, educational programs for patients and doctors, and the improvement of reimbursement system should be considered in Korea.

show abstract

“…According to data obtained in postmenopausal women, a daily intake of at least 800 IU should be advised together with a daily calcium intake (from food and supplements) of 1,000 mg. The intake of calcium from the diet should be favoured because it has been suggested that high doses of calcium supplements were associated with increased cardiovascular risks [153]. These recommendations have been extended from National Comprehensive Cancer Network (NCCN) Bone Health in Cancer Care Task Force to premenopausal women at risk of cancer treatment-associated bone loss.…”

Section: Prevention Of Bone Loss and Fracturesmentioning

confidence: 99%

Cancer-associated bone disease

Rizzoli

Body²,

Brandi³

et al. 2013

Osteoporos Int

122

103

View full text Add to dashboard Cite

Bone is commonly affected in cancer. Cancer-induced bone disease results from the primary disease, or from therapies against the primary condition, causing bone fragility. Bone-modifying agents, such as bisphosphonates and denosumab, are efficacious in preventing and delaying cancer-related bone disease. With evidence-based care pathways, guidelines assist physicians in clinical decision-making. Of the 57 million deaths in 2008 worldwide, almost two thirds were due to non-communicable diseases, led by cardiovascular diseases and cancers. Bone is a commonly affected organ in cancer, and although the incidence of metastatic bone disease is not well defined, it is estimated that around half of patients who die from cancer in the USA each year have bone involvement. Furthermore, cancer-induced bone disease can result from the primary disease itself, either due to circulating bone resorbing substances or metastatic bone disease, such as commonly occurs with breast, lung and prostate cancer, or from therapies administered to treat the primary condition thus causing bone loss and fractures. Treatment-induced osteoporosis may occur in the setting of glucocorticoid therapy or oestrogen deprivation therapy, chemotherapy-induced ovarian failure and androgen deprivation therapy. Tumour skeletal-related events include pathologic fractures, spinal cord compression, surgery and radiotherapy to bone and may or may not include hypercalcaemia of malignancy while skeletal complication refers to pain and other symptoms. Some evidence demonstrates the efficacy of various interventions including bone-modifying agents, such as bisphosphonates and denosumab, in preventing or delaying cancer-related bone disease. The latter includes treatment of patients with metastatic skeletal lesions in general, adjuvant treatment of breast and prostate cancer in particular, and the prevention of cancerassociated bone disease. This has led to the development of guidelines by several societies and working groups to assist physicians in clinical decision making, providing them with evidencebased care pathways to prevent skeletal-related events and bone loss. The goal of this paper is to put forth an IOF position paper addressing bone diseases and cancer and summarizing the position papers of other organizations. Epidemiology of cancer-associated bone disease Bone metastasisCancer affects nearly 12.7 million people and is associated with over 7 million deaths in 2008 [1]. Cancer is a rising global health burden and it is estimated that in 2030, cancer deaths will be tallied at over 13 million (World Health Organization (WHO) 2010 Global Status Report [2]). Addressing the morbidity and mortality of cancer is an important public health concern. On purpose, we are limiting our analysis to cancer bone involvement in adults and do not discuss cancer in children.Metastases from cancer are associated with 90 % of cancer deaths [3]. It was estimated that one half of people who die from cancer in the USA have bone involvement [4][5][6]. Different tumou...

show abstract

Calcium supplements and cardiovascular risk in the Women’s Health Initiative

Cited by 3 publications

References 6 publications

Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures

Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures

Physicians' Attitudes to Contemporary Issues on Osteoporosis Management in Korea

Cancer-associated bone disease

Contact Info

Product

Resources

About